The use of TNF-α inhibitors in children serves as a critical therapeutic approach for refractory conditions, particularly in diseases such as JIA and pediatric IBD [10], which demonstrate higher rates of treatment resistance. The gene discussed is TNF; the disease is inflammatory bowel disease.